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Available online 14 May 2016A library of isoquinolinone and azepanone derivatives were screened for both acetylcholinesterase
(AChE) and butyrylcholinesterase (BuChE) activity. The strategy adopted included (a) in vitro biological
assays, against eel AChE (EeAChE) and equine serum BuChE (EqBuChE) in order to determine the com-
pounds IC50 and their dose-response activity, consolidated by (b) molecular docking studies to evaluate
the docking poses and interatomic interactions in the case of the hit compounds, validated by STD-NMR
studies. Compound (1f) was identified as one of these hits with an IC50 of 89.5 lM for EeAChE and
153.8 lM for EqBuChE, (2a) was identified as a second hit with an IC50 of 108.4 lM (EeAChE) and
277.8 lM (EqBuChE). In order to gain insights into the binding mode and principle active site interactions
of these molecules, (R)-(1f) along with 3 other analogues (also as the R-enantiomer) were docked into
both RhAChE and hBuChE models. Galantamine was used as the benchmark. The docking study was val-
idated by performing an STD-NMR study of (1f) with EeAChE using galantamine as the benchmark.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Life style improvement as well as better health care, coupled
with significant advances in medical technologies in the last cen-
tury, has permitted an increase in average life expectancy, however
the downside is the increased incidence of dementia in the global
population. In 2010, estimates pointed to 35.6 million people with
dementia worldwide, a number that is expected to double every
20 years, reaching 115.4 million cases in 2050, 60–70% of which
have been assigned to Alzheimer’s disease (AD) [1]. This is the
most common form of dementia and causes a progressive and irre-
versible neurodegeneration. AD is related with loss of cholinergic
function, which affects memory, learning and behavior [2]. A large
part of the strategies for treating AD have been based on the
cholinergic hypothesis, which postulates that memory loss in Alz-
heimer’s patients is associated with a deficit of cholinergic functionin the brain [3,4]. The loss of cholinergic neurons leads to the pro-
gressive reduction of acetylcholine (ACh) in the brain and resulting
cognitive impairment in AD [5]. As such, the enzyme acetyl-
cholinesterase (AChE) has been one of the prime targets in the
search for a treatment for AD, which uses reversible inhibitors of
AChE, in order to increase levels of ACh in the brain [6,7]. ACh is
hydrolyzed by both AChE and butyrylcholinesterase (BuChE).
Although little is known about the physiological role of BuChE
[8,9], particularly in the central nervous system, studies have been
made in order to determine its influence on the treatment of AD
[10,11]. It was found that in the course of the disease, levels of
AChE in the CNS decrease contrary to what happens with BuChE
[12]. Both enzymes represent legitimate therapeutic targets for
ameliorating the cholinergic deficit characteristic of AD.
Considering their broad biological activity spectrum, the iso-
quinolinone scaffold is a privileged-scaffold lead for targeting var-
ious diseases and these compounds were chosen for this study
[13]. Isoquinolines are alkaloids found in several bioactive natural
products [14–17]. They are biogenetically derived from phenylala-
nine [18], and exhibit antidepressant [19], anti-inflammatory [20]
and analgesic [21,22] characteristics. For this reason this family
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panone family was chosen on the basis of their analogy with galan-
tamine which contains an azepane ring, and it is the azepane ring
which is recognized as the important pharmacophore element for
ChE inhibition (see below).
The objective of the present study was to evaluate the inhibi-
tory capacity of a series of isoquinolinone and azepanone deriva-
tives for AChE and BuChE targets. The biological assays involved
a modified in vitro Ellman method [6,23]. Furthermore, by compar-
ing the IC50 values and AChE selectivity index (SI, IC50 BuChE/IC50
AChE) and by analyzing the inhibitor-enzyme interaction using
docking studies combined with STD-NMR validation studies, we
obtained important insights on the nature of the interaction of
these molecules with the enzyme active site, making the design
of better ChE inhibitors (ChEIs) possible.2. Results and discussion
2.1. Chemical synthesis
In an earlier report by our group [24], an innovative transition-
metal-catalysed intramolecular cyclization reaction of amido(het-
ero)arylboronic acid aldehydes to isoquinolin-1(2H)-one deriva-
tives was developed. Starting from easily accessed acetal
substrates, an efficient three-step synthetic approach was reportedScheme 1. Our reported synthetic route to the isoquinolin-1(2H)-one derivatives. (a) Pd
[Rh(COD)Cl]2, K2CO3, Toluene, 100 C, 24 h. Reproduced from Ref. [24].[24] (Scheme 1). A library of 16 isoquinolinone and azepanone
derivatives (Schemes 1 and 2) were tested for cholinesterase
inhibition.
The isoquinolinone derivative (1f) was obtained in 28% yield,
from the iodide-acetal derivative in the first synthetic step, at
100 C (see Scheme 2). This approach failed using the other acetal
derivatives, however we decided to test compound (1f) to evaluate
the importance of the 4-hydroxyl group on the ChE inhibition, as
(1f) contains a 4-methoxyl substituent. We are currently investi-
gating the mechanism of formation of this interesting compound,
so that we can improve the synthetic method and enlarge the reac-
tion scope.2.2. In vitro inhibition studies for AChE and BuChE
The biological assays to determine the compound IC50 followed
a method based on the in vitro Ellman reaction [13,23,25]. We used
Electrophorus electricus (eel) AChE (EeAChE) and equine serum
BuChE (EqBuChE) as they are readily commercially available. The
results of these inhibition studies are shown in Table 1. The
dose-response curves of both EeAChE and EqBuChE are presented
in Fig. 1. In the case of AChE, compound (1f) provided the best
inhibition value (Table 1, entry 6), showing the importance
of the methoxyl group in position-4 (compare entries 1 and 6,
Table 1). The presence of electron withdrawing and weaklyCl2(dppf), HBPin, NEt3, 1,4-dioxane, 80 C, 18 h. (b) HCl (1 M), THF, 100 C, 12 h. (c)
Scheme 2. Synthetic route of isoquinolin-1(2H)-one (1f) (previously not reported).
Table 1
Inhibition studies for AChE and BuChE.








1 1a 136.0 ± 8.8 807.5 ± 1.9 5.938
2 1b >1500 352.1 ± 17.7 N.D.
3 1c >1500 >1500 N.D.
4 1d >1500 226.1 ± 20.8 N.D.
5 1e 311.3 ± 2.3 >1500 N.D.
6 1f 89.5 ± 2.0 153.8 ± 2.6 1.718
7 2a 108.4 ± 3.4 277.8 ± 7.7 2.563
8 2b 536.3 ± 37.7 108.0 ± 8.1 0.201
9 2c 564.4 ± 21.8 269.4 ± 6.5 0.477
10 2d 585.1 ± 23.6 108.6 ± 15.7 0.186
11 3a 1296.7 ± 22.8 >1500 N.D.
12 3b 1251.7 ± 180.9 >1500 N.D.
13 4a 550.4 ± 17.8 >1500 N.D.
14 4b >1500 >1500 N.D.
15 5 1366.2 ± 48.9 >1500 N.D.
16 6 756.4 ± 24.4 825.6 ± 16.1 1.091
17 Galantamine 3.5 ± 0.5 61.9 ± 5.2 0.05
N.D. - Not detected at the concentrations tested.
a IC50 values are expressed as mean ± SD (n = 3) based on dose-response curves,
using the Origin 8.0 Pro.



























































Fig. 1. Dose-response curves for compounds (1a), (1f), (2a), (2b) and rivastigmine for EeA
inhibition. (Rivastigmine which is a dual ChE inhibitor was used as the benchmark).
P. Bacalhau et al. / Bioorganic Chemistry 67 (2016) 1–8 3electron-donating substituents in the aryl ring of isoquinolin-1
(2H)-ones derivatives was found to affect the IC50 value consider-
ably (see for instance entries 2–4, Table 1) since they give very
weak activities. In the case of compound (1e) – bearing the stron-
ger methoxyl electron-donating group in the 8-position, a better
IC50 of 311.3 lM (Table 1, entry 5) was obtained, this may have
been due to stronger electron donation or perhaps due to effective
binding of the methoxyl group in the enzyme active site. Compar-
ing the azepanone compounds with their isoquinolinone counter-
parts it was noticed that (2b)–(2d) (with the isoquinolinone unit)
were shown to be at least three times more potent than (1b)–
(1d) (with the azepanone unit) (Table 1, compare entries 7–9 with
2–4). (2a) was the exception in that it had a similar value to com-
pound (1a) (Table 1, entries 1 and 7). However, in the case of both
the azepanone and the isoquinolinone families, it was observed
that aromatic substitution was deleterious for activity. Azepin-1
(2H)-ones with pyridyl cores, regardless of having electron donor
groups in the aryl ring or not gave similar IC50 values for EeAChE,
compound (4a) (IC50 of 550 lM) was the best candidate (Table 1,
compare entries 11–14). In the context of AChE inhibition, there
was a big difference observed in the two molecules containing a
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Fig. 2. Schematic representation of the active site gorge of EeAChE based on that of
TcAChE [28b].
4 P. Bacalhau et al. / Bioorganic Chemistry 67 (2016) 1–8IC50 almost twice that of azepin-1(2H)-one (6) (Table 1, entries 15
and 16, respectively). When compared to the galantamine
benchmark, all our compounds showed higher IC50 values for
both ChEs. Galantamine is a specific AChE inhibitor (see below
for further discussion), but was used in this study with both
enzymes.
In the case of BuChE, the azepin-1(2H)-one compounds gave
better results than their isoquinolin-1(2H)-one counter-parts,
independently of the type of substituent in the aryl ring. Com-
pounds (2b) and (2d) gave the best IC50 values, which were
108.0 lM and 108.6 lM, respectively (Table 1, entries 8 and 10).
Good IC50 values were also obtained for the isoquinolin-1(2H)-
ones, as compound (1f) (Table 1, entry 6) gave an IC50 value of
153.8 lM, which is the best result for these compounds with this
enzyme. Moreover, the pyridyl and thiophene containing deriva-
tives, regardless of the ring size, did not present any major differ-
ences in their IC50 values (Table 1, entries 11–15), and displayed
poor inhibition. Unfortunately, all these compounds were less
active with EqBuAChE than the benchmark (all presented higher
IC50 values). Compound (2b) gave the lowest value of 108.0 lM.
As can be seen from Table 1, and the selectivity indexes, the
isoquinolin-1(2H)-ones and azepin-1(2H)-ones with no sub-
stituents in the aryl ring, and the isoquinolinones and azepin-1
(2H)-ones with pyridyl and thiophene units were selective for
AChE, whilst isoquinolin-1(2H)-ones and azepin-1(2H)-ones with
substituents in the aryl ring were selective for AChE.
Analysis of the dose-response curves (Fig. 1) revealed some
interesting insights. Both compounds (1f) and (2a) showed similar
behavior for EeAChE and EqBuChE inhibition (Fig. 1), this along
with the respective IC50 values (Table 1), makes these compounds
potential target inhibitors for both enzymes, and a structural basis
for lead development design. Compound (1a) presented a dose-
response curve compatible with its corresponding IC50 value and
shows potential to be a target drug for AChE (Fig. 1). Compounds
(1e), (3a), (3b), (4a), (4b), (5) and (6) act as EeAChE activators at
concentrations lower than 120.2, 426.6, 346.7, 331.1, 446.7,
363.1 and 190.5 lM, respectively (Fig. S1, supplementary informa-
tion). For higher concentrations they act as inhibitors. It is not yet
clear why these compounds show this behavior. The same is true
for the EqBuChE inhibitors (2d) and (3b) that act as activators for
concentrations lower than 61.7 and 93.8 lM, respectively. For con-
centrations above 61.7 lM, compound (2d) shows good inhibition
of EqBuChE (Fig. S1). In the case of compound (1d), for EqBuChE it
presented an IC50 of 226.1 lM, but at half this concentration it pre-
sented a significant 40% inhibition and at a quarter the IC50 concen-
tration, 30% inhibition (Fig. 1). Compound (2c) presented an IC50 of
564.4 lM for EeAChE, but at a concentration 2.5 times lower it gave
a significant 30% inhibition. The same behavior was observed for
compound (2d) in the case of EeAChE inhibition (Fig. S1).
Although compounds (3b), (5) and (6) were found to be poor
inhibitors of EeAChE and EqBuChE we can see from Fig. S1 that their
dose response curves overlap at a concentration of 912.0 lM (40%
inhibition), 1000.0 lM (40% inhibition) and 512.9 lM (30% inhibi-
tion), respectively.
2.3. Binding mode characterization using docking studies
Critical to structure-based drug discovery is computational
docking, which explores the position of small molecules within
the binding site of the target biomacromolecule [26,27]. Cho-
linesterases are among the most efficient enzymes known. EeAChE
(which we used in our bioactivity screening studies) possesses the
three amino acids of the catalytic triad S203, E334 and H447, the
aromatic residues F295 and F297, which define an acetylcholine-
specific acyl pocket, the tryptophan residue W86, which interacts
with the choline moiety in the active site, G121 and G122 - whichon the basis of structural analogy with TcAChE (see below in Fig. 2)
would be part of the oxyanion hole - as well as the 14 aromatic
residues lining the walls of a deep narrow gorge of about 20 Å
(Fig. 2) [28]. All 14 amino acids in the aromatic gorge are highly
conserved across different species [28b]. Together with W86,
Y337 constitutes the choline-binding subsite of the catalytic site
[29]. Unfortunately, little structural information is available for
EeAChE in contrast to Torpedo californica (ray) AChE (TcAChE)
whose structure has been studied extensively, and we use as the
basis of our model for EeAChE depicted in Fig. 2 [28b]. Thirteen
of the gorge amino acid residues in EeAChE are identical to
TcAChE, but Y330 of EeAChE is replaced by F330 in TcAChE [28].
The X-ray crystallographic analysis of TcAChE showed that it con-
sists of a catalytic triad (S200-H440-E327) which lies close to the
bottom of the deep and narrow gorge, which is lined with 14 aro-
matic amino acid residues [30a–30c]. Despite the complexity of
this array of aromatic rings, it was suggested, on the basis of mod-
elling with the active site of TcAChE - which involved docking of
the acetylcholine (ACh) molecule in an all-trans configuration, -
that the quaternary group of the choline moiety makes close con-
tact with the indole ring of W84 [28b,30b].
Human BuChE (hBuChE) and human AChE (hAChE) share 65%
amino acid sequence homology [31]. The crystal structure of
(hBuChE) has already been solved [31b,31c]. This enzyme can
hydrolyze toxic esters such as cocaine and scavenge
organophosphorous pesticides and nerve agents [31b]. It is
characterized by possessing the catalytic triad, S198, E325 and
H438, the hydrophobic residues L286 and V288, which define the
acyl pocket [31b]. The tryptophan amino acid residue W82,
interacts with the choline moiety in the catalytic active site via a
p-cation interaction. The residues D70, Y332 and N83 constitute
the peripheral anionic site (PAS) [13]. When compared, both
TcAChE and hBuChE have the catalytic triad at the bottom of the
gorge (20 Å deep). In the case of TcAChE the gorge consists of aro-
matic residues and in the case of EqBuChE the gorge has hydropho-
bic residues. In contrast to TcAChE, the EqBuChE acyl pocket has
smaller, hydrophobic, amino acid residues, so it can accommodate
bulkier inhibitors than in the case of AChE. In both enzymes the
PAS is located at the outer rim of the gorge, and is an attraction
center for substrates. The anionic site for both TcAChE and
P. Bacalhau et al. / Bioorganic Chemistry 67 (2016) 1–8 5EqBuChE is found half-way down the gorge, between the periph-
eral and the acylation sites.
As we used EeAChE and EqBuChE for our bioassays and STD
studies (see below), prior to conducting our molecular modelling
studies we conducted sequence alignment studies, between,
EeAChE and hAChE, and between EqBuChE and hBuChE (Figs. S2
and S3). What we saw was an overall identity of 88% and 90% for
AChE and BuChE, respectively and no differences were detected
for the amino acid sequences within the active sites between the
human and non-human sources.
We analyzed and quantified the protein-ligand interactions by
performing a computational docking that provides insight into
molecular recognition for the cholinesterase inhibition assay. In
our computational method, we used both recombinant human
AChE (RhAChE) and human BuChE (hBuChE) crystal structures as
input structures. We docked only the (R)-enantiomer in each case,
even though the racemic mixture was used in the bioassays, on the
basis that in the case of galantamine the stereogenic centre to
which the 6-OH group attached has the (R)-configuration, and this
would appear to be a stereochemical requisite for favorable ligand-
enzyme interaction. The binding modes of (R)-(1f) and (R)-(2b),
were expected to provide insights into their relatively good inhibi-
tion of both eeAChE and eqBuChE (see Figs. 2 and 3) and allow us to
design a series of stronger binding lead compounds. Interestingly,Fig. 3. Comparison of the binding mode of compound (R)-(1f) obtained by docking. (a)
ligand interaction of (R)-(1f) with hBuChE. Hydrogen bonds are shown as green dotted li
site (grey color). Water molecules in the active site are represented as red spheres.(R)-(1f) showed H-bonding (amide group) with the oxyanion
pocket (G121, 2.92 Å, and G122, 3.04 Å), suggesting that it could
inhibit AChE in a novel manner (unfortunately this could not be
confirmed in our STD-NMR study – see below). Furthermore, the
carbonyl oxygen of the amide formed a H-bond with S203
(2.60 Å) whilst, the methoxyl oxygen formed a H-bond with
Y124 (2.88 Å). Remarkably, a p-p stacking hydrophobic interaction
formed between the aromatic ring of (R)-(1f)with theW86 residue
at the anionic binding site of AChE, possibly stabilizing the ligand-
protein complex (Fig. 3a). The structural modification of (R)-(1f) to
(R)-(1e) - the latter having a methoxyl group in the aromatic ring,
and a 4-OH group - showed a conformational change that favors a
p-p stacking interaction formed from the aromatic ring of (R)-(1e)
with both W86 and F297 (Fig. S4). Furthermore, the amide nitrogen
of (R)-(1e) formed a H-bond with the carboxylic OH of E202. The
interaction with the oxyanion pocket as was the case with (1f)
was not evident for (1e), and this may explain its poorer binding
affinity (see Table 1). To compare the binding mode of (R)-(1f) in
the BuChE active site (Fig. 3b), a favorable H-bond network was
formed with the two conserved water molecules. We have shown
previously that water molecules that are close to the binding site
can lead to a conformational change that favors binding of the inhi-
bitors [32]. These water molecules can be described as ‘‘sticky
water” molecules and enhance the protein-ligand binding. OurDisplay of protein ligand interaction of (R)-(1f) with hRAChE. (b) Display of protein
nes, formed between the ligand (R)-(1f) (green color) with the residues in the active
6 P. Bacalhau et al. / Bioorganic Chemistry 67 (2016) 1–8studies showed that the presence of sticky water molecules were
beneficial only in the case of BuChE, perhaps because of its larger
gorge.
Specifically, the first water molecule formed interactions with
S79 (2.80 Å), D70 (2.68 Å), and the (R)-(1f) aromatic N (3.01 Å),
whereas, the second water molecule formed an interaction with
T120 (2.84 Å). In addition, the hydroxyl group O3 of Y332 formed
two H-bonds with the N of (R)-(1f) (3.03 Å) and its carbonyl O2
(2.79 Å).
(R)-(2b) was also studied with hBuChE as it afforded the best
inhibition values (Table 1). The predicted binding mode of (R)-
(2b) with hBuChE (Fig. 4b) indicated a strong stabilization of the
complex around the PAS-site, which can be attributed to hydrogen
bond networks. The bridging of the two water molecules in the
active site includes H-bonds of the first water molecule with the
carbonyl O2 of (R)-(2b) (1.86 Å), the hydroxyl of S79 (2.80 Å),
and the carbonyl of D70 (2.68 Å) respectively, whereas, the second
water molecule formed a H-bond with the O3 of T120 (2.84 Å). Fur-
thermore, the (R)-(2b) nitrogen formed a strong H-bond with O2 of
Y332 (2.95 Å), whilst the (R)-(2b) hydroxyl group O3 formed a H-
bond with the aromatic N of W82 (3.03 Å). Compound (2d) pre-
sented almost the same inhibition for EqBuChE as (2b). Interest-
ingly, when the methyl group in (R)-(2b) was substituted with a
methoxyl group in (R)-(2d) as shown in Fig. S5 (supplementary
information), there was a shift in the interaction of the amide NFig. 4. Comparison of the binding mode of compound (R)-(2b) obtained by docking. (a) D
interaction of (R)-(2b) with hBuChE. Hydrogen bonds are shown as green dotted lines, fo
(grey color). Water molecules in the active site are represented as red spheres.to form a H-bond with Y440 (2.79 Å), instead of with Y332. Also
there were other significant interactions, like: a p-p stacking inter-
action with W82, a H-bond between the 4-OH oxygen and the
Y440 residue, along with a tight H-bond network formed between
the carbonyl oxygen (1.98 Å), A70 (2.68 Å) and S79 (2.8 Å) and a
water molecule.
Overall, a significantly weaker interaction was found in the (R)-
(2b)-RhAChE complex (Fig. 4a), there was a p-p stacking interac-
tion with W86 and two H-bonding interactions with E202
(2.797 Å) and S203 (2.65 Å), and this would explain its lower bind-
ing for EeAChE as compared to EqBuChE.
To finalize this section the following point should be noted; dif-
ferences in results between the computational docking study and
the experimental inhibition bioassays were inevitable, because
(1) RhAChE and hBuChE crystal structures were used as input
structures in the computational study whereas, eeAChE and
eqBuChE were used in the bioassay and (2) only the (R)-
enantiomers of the hit compounds were docked, whereas the race-
mic mixtures was screened in the bioassays.
3. Saturation Transfer Difference - Nuclear Magnetic Resonance
(STD - NMR)
To validate the docking studies, we performed key STD-NMR
experiments to map the ligand-protein interactions of compoundisplay of protein ligand interaction of (2b)with hRAChE. (b) Display of protein ligand
rmed between the ligand (R)-(2b) (green color) with the residues in the active site
Fig. 5. STD-NMR study of compound (1f) with both EeAChE and EqBuChE, performed at 400 MHz, 15 C, and 3 s saturation time. (A) reference spectrum, (B) STD spectrum of
compound (1f) (0.8 mM) with EeAChE enzyme (4 lM) and (C) STD spectrum of compound (1f) (0.8 mM) with EqBuChE enzyme (4 lM). Binding epitope of (1f) from STD NMR
experiment. The numerical values designate the fraction of saturation as a percentage, between the ligand protons and the protein active site, based on the maximum ligand
STD signal (H1,3 of Ar; 100%).
P. Bacalhau et al. / Bioorganic Chemistry 67 (2016) 1–8 7rac-(1f) (Fig. 5) with both EeAChE and EqBuChE. The reference inhi-
bitor used for these STD studies was galantamine (Fig. S6). To pre-
cisely map ligand epitopes in close contact with the protein, we
acquired STD build up curves by collecting spectra at different sat-
uration times [33–36]. The observed STD amplification (ASTD) is not
the same for all the hydrogen molecules in compound (1f) (Fig. 6),
as well as for galantamine (Fig. S7c). This is due to the fact that not
all the proton signals in the STD-NMR spectrum received the same
amount of saturation [33,34]. Thus, the distribution of saturation
transferred among the different compound protons indicates spa-
tial proximities between the protons of the compound molecule
and the enzyme in the bound state [37]. Qualitatively, it can be
assumed that a stronger intensity of a compound signal in theFig. 6. STD amplification factor as a function of saturation time for a 200-fold (1f)
excess of EeAChE.STD-NMR spectrum indicates closer inter-hydrogen distances
between the compound proton and the receptor surface in the
bound state [34]. To quantitatively express the relative STD effects
at a given saturation time, all of the STD signals are normalized
against the most intense signal, which is arbitrarily assumed to
be 100% [37]. It can be concluded that protons with relative STD
values close to 100% belong to parts of the compound that are very
intimately recognized by the receptor binding-pocket, and hence
must be regarded as important for the interaction.
Galantamine was chosen as it is a selective AChE inhibitor con-
taining an azepanone unit, and is known to form a tight complex
with TcAChE [38–40]. In the galantamine-TcAChE case, the amino
acids residues that are within close proximity (i.e. defined as less
than 5 Å) were E199, F330, W84, H440, F288, F290, Y121, F331,
G119, S200, G118, and G117 [38–40]. It binds principally with
W84 (but not via the amine nitrogen N-10 [40]) in the anionic
binding site and F288 and F290 of the peripheral anionic site
(PAS) at the entrance to the gorge. The crystal structure of
galantamine-RhAChE was also determined and the binding was
deemed to be similar to that of galantamine-TcAChE [40]. However,
an additional hydrogen bond was formed between the galantamine
N-10 and Y337, which was in a different orientation than the cor-
responding F330 of TcAChE [41].
We conducted an STD-NMR study of the complex formed
between EeAChE (commercially available and cheap) and galan-
tamine (Fig. S4 and S5). It showed important interactions between
the aromatic ring protons (H6, 100% and H5 68%) and the enzyme,
with the stronger interaction coming from H6. On comparing this
with the report by Greenblatt et al. [38], this was presumably a
p-p interaction with most likely F295 or F297 of our enzyme (in
8 P. Bacalhau et al. / Bioorganic Chemistry 67 (2016) 1–8the report by Greenblatt et al. [38] a proximity of these protons
with the F331 residue was observed). The methoxyl group and
the methyl group attached to N10 also showed significant interac-
tion (62% and 51%, respectively). In the case of the methoxyl group
this was probably due to H-bonding with H447 (in the study by
Greenblatt et al. [38] there was a close approximation of H440 with
the MeO group). The OH group also showed a significant interac-
tion with the enzyme, registering an STD value of 53%, and analo-
gous to the X-ray crystal information [38] probably due to a H-
bond interaction with G121 or G122 (in the literature report there
was a good approximation between the OH and G117). The signif-
icant values of 37% and 30% observed for H-15 and H-9, could prob-
ably be due to a p-p and CH/p interaction [42] with W86. As in the
X-ray crystal structure the W84 indole was observed very close to
this region of the molecule (Fig. S6 and S7).
In the case of compound (1f), it was inferred that the hydrogen
atoms namely, H1 and H3 were directly involved in the binding to
the AChE and BuChE active sites (Fig. 5B and C). According to this
qualitative analysis, the aromatic hydrogens (Fig. 5B and C) and
the hydrogens from the methoxyl group (Fig. 5C), were observed
to be strongly involved in the binding. In contrast, the hydrogens
H7, H8a, H8b and H11 showed a relatively lower STD value, indi-
cating that they were probably more distant from the active site
residues for both enzymes [39]. Unfortunately as we could not
localize the NH peak in the 1H NMR spectrumwe could not confirm
if there was an interaction of the NH proton with the enzyme.
These results are in agreement with the molecular docking predic-
tion, even though in the case of the docking study a single enan-
tiomer was used and in the STD-NMR rac-(1f) used. Inorder to
support this hypothesis, much effort was made at accessing appro-
priate N-alkylated derivatives [24b], but due to purification issues
it was not possible to isolate these derivatives in pure form.4. Conclusions
From a series of bioassay studies on EeAChE and EqBuChE inhi-
bition, compounds (1f) and (2a) were identified as two hit com-
pounds that can be modified to furnish a series of lead
compounds. Molecular docking showed that the amide NAH
group, the 4-methoxyl group and the azepanone core show good
binding characteristics with both enzyme active sites. Compounds
(2b) and (2d) showed the best IC50 values for EqBuChE, indicating
their potential as BuChE inhibitors. Compound (1f) showed H-
bonding with the oxyanion pocket suggesting that it could inhibit
AChE in a novel manner and a p-p stacking interaction between its
aromatic ring and the W86 residue in the anionic binding site, can
give favorable stabilizing interactions in the ligand-protein com-
plex. These assumptions have been validated by STD-NMR (unfor-
tunately it could not confirm the NAH interactions in (1f) and
(2a)), which showed a strong interaction between the aromatic
ring and the AChE active site.
Overall the compounds studied are weak ChEIs, but nonethe-
less, important insights have been obtained on their mode of inhi-
bition so that more potent analogues can be designed, prepared
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